Navigation Links
Geisinger study: Inflammatory disease causes blindness
Date:6/16/2008

DANVILLE, PA. People suffering from a type of connective tissue disease characterized by inflammation of arteries in the head are three times more likely to experience blindness, new Geisinger research shows.

In a study published in a recent edition of the Journal of Clinical Pathology, Geisinger researchers examined a disorder known as temporal arteritis. In this disease, arteries swell and restrict blood flow to the brain.

Temporal arteritis can cause headaches, jaw soreness and flu-like symptoms. Untreated, the disease can lead to blindness or stroke. The average age for disease onset is 70.

Giant cells, which are white blood cells that destroy bacteria, are often found in patients with the disease. The Geisinger study found that patients with giant cells are far more prone to blindness compared to patients without these cells.

The study also found that patients with giant cells are three times more likely to experience Polymyalgia rheumatica, an inflammatory disorder that causes muscle aches and stiffness primarily in the arms, thighs and neck.

"We need to learn more about how these giant cells work so we can limit the effects of this disease, which can cause significant problems if ignored," said Geisinger rheumatologist and lead study author Thomas Harrington, MD.


'/>"/>

Contact: Justin Walden
jawalden@Geisinger.edu
570-271-8083
Geisinger Health System
Source:Eurekalert

Page: 1

Related biology news :

1. Study: diabetic neuropathy costs billions per year in lost work time
2. Study: Fountain of youth for your heart?
3. First-ever study: lack of critical lubricant causes wear in joints
4. Mayo Clinic study: Ossurs collars superior in immobilization and reduction of pressure
5. Study: weight-loss tips differ in African-American, mainstream magazines
6. Smithsonian study: Sediment prediction tools off the mark
7. Mouse study: When it comes to living longer, its better to go hungry than go running
8. Scientists successfully treat new mouse model of inflammatory bowel disease
9. Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment
10. Antioxidant overload may underlie a heritable human disease
11. Gender, coupled with diabetes, affects vascular disease development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: